Promising combo for Hard-to-Treat ovarian cancer never got off the ground
NCT ID NCT04149145
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether a new drug called M4344, combined with the PARP inhibitor niraparib, could be safe and effective for women with recurrent ovarian cancer that had stopped responding to PARP inhibitors. The plan was to enroll women with advanced ovarian, primary peritoneal, or fallopian tube cancer who had progressed on a PARP inhibitor. However, the trial was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M4344 and niraparib (combination drug therapy)
What this could lead to
If it had worked, this could have pointed toward a new treatment option for ovarian cancer that no longer responds to PARP inhibitors.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It was also a very early Phase 1 study, meaning safety and dosing were still being figured out.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.